Minakata, Daisuke http://orcid.org/0000-0002-0217-8107
Ishida, Tadao
Ando, Kiyoshi
Suzuki, Rikio
Tanaka, Junji
Hagiwara, Shotaro
Ananthakrishnan, Revathi
Kuwayama, Shigeki
Nishio, Mitsufumi
Kanda, Yoshinobu
Suzuki, Kenshi
Funding for this research was provided by:
Bristol Myers Squibb K.K.
Article History
Received: 3 October 2022
Revised: 6 January 2023
Accepted: 9 January 2023
First Online: 24 January 2023
Declarations
:
: DM: nothing to declare. TI: grants or contracts from Alexion, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; payment or honoraria from Bristol Myers Squibb, Janssen, ONO, Sanofi, and Takeda. KA: research funding from Chugai, Kyowa Kirin, and Takeda. RS: payment or honoraria from Janssen. JT: nothing to declare. SH: research funding from and participation on advisory board for Bristol Myers Squibb. RA: employee and stockholder of Bristol Myers Squibb; leadership or fiduciary role in other board, society, committee, or advocacy group for ASA NJ Princeton-Trenton Chapter (President). SK and MN: employee and stockholder of Bristol Myers Squibb K.K. YK: research grants from Bristol Myers Squibb, ONO, and Takeda; payment or honoraria for lectures from Bristol Myers Squibb, Janssen, Novartis, Sanofi, and Takeda. KS: honoraria from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Novartis, ONO, Sanofi, and Takeda; consulted for Amgen, Bristol Myers Squibb, and Takeda; received research funding from Bristol Myers Squibb.